Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 2 pilot study of oral PRN1008 in pemphigus vulgaris
MOH_2017-10-02_000846Phase 2Completed
- Sponsor
- Principia Biopharma
- Start
- Apr 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rilzabrutinib in pemphigus vulgaris (PV), sponsored by Principia Biopharma. Primary endpoints: Safety and Clinical activity. Started Apr 2016; status: completed.
02
Drugs
rilzabrutinib
03
Conditions
pemphigus vulgaris (PV)
Beyond the preview
Go deeper on MOH_2017-10-02_000846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-10-02_000846.